Notably, the PAL nanoparticles containing p53 mRNA demonstrated a synergistic cytotoxic effect in triple-negative breast cancer cells, combining the therapeutic effects of both paclitaxel and p53 mRNA. Here, TP53 is linked to triple-negative breast carcinoma.